Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals to Present at Upcoming Virtual Investor Conferences

Business Wire September 8, 2020

Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy

Business Wire September 2, 2020

Catabasis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Reviews Business Progress

Business Wire August 10, 2020

Catabasis Pharmaceuticals to Present at Virtual 2020 Wedbush PacGrow Healthcare Conference

Business Wire August 5, 2020

Catabasis Pharmaceuticals and Bill & Melinda Gates Medical Research Institute to Study CAT-5571 in Drug-Sensitive and Drug-Resistant Tuberculosis

Business Wire August 4, 2020

Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th

Business Wire July 27, 2020

Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference

Business Wire July 15, 2020

Catabasis Joins Russell 3000® Index

Business Wire June 29, 2020

Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel

Business Wire June 12, 2020

Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business Progress

Business Wire May 12, 2020

Catabasis Pharmaceuticals Presents Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy

Business Wire May 12, 2020

Catabasis Pharmaceuticals to Report First Quarter 2020 Financial Results on Tuesday, May 12th

Business Wire April 28, 2020

Catabasis Pharmaceuticals to Present at 2020 Muscular Dystrophy Association Virtual Poster Session

Business Wire April 17, 2020

Catabasis Pharmaceuticals to Present at the Upcoming 2020 Solebury Trout Virtual Investor Conference

Business Wire March 25, 2020

Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

Accesswire March 24, 2020

Catabasis Pharmaceuticals to Present During the Muscular Dystrophy Association Virtual Clinical Trials Session

Business Wire March 18, 2020

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Reviews Business Progress

Business Wire March 10, 2020

Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Developments on Tuesday, March 10th

Business Wire February 25, 2020

Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy

Business Wire February 21, 2020

Catabasis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Over-Allotment Option

Business Wire February 3, 2020